Emergency Medicine in Haemostasis Disorders

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Emergency Medicine".

Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 1083

Special Issue Editor

Special Issue Information

Dear Colleagues,

Thrombosis, a life-threatening complication, is a significant cause of morbidity and mortality in cardiovascular disease. Over the past few decades, advanced progress has been made in managing thrombotic disorders in emergency and critical care, including medications, endovascular therapy, and surgical intervention. Moreover, improving the quality of care is also pivotal in decreasing the time to revascularization and managing complications.

The main aim of this Special Issue of Medicina is to highlight contemporary advances in acute care for thrombotic disorders in emergency and critical care. This Special Issue is open to studies for new techniques or strategies, decision making, clinical outcome research, quality improvement, and systematic reviews and meta-analyses in care for thrombotic disorders.

In this Special Issue, papers focused on thrombotic disorder care updates are highly welcomed. We wish to solicit studies from different perspectives, including emergency, critical care, nursing care, quality improvement, bench or clinical study design, case management, pharmacological therapy, endovascular or surgical intervention, and meta-analysis.

Dr. Pierpaolo Di Micco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • venous thromboembolism
  • pulmonary embolism
  • disseminated intravascular coagulation
  • hypercoagulable state
  • antithrombotics
  • anticoagulants
  • thrombophilia

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 303 KiB  
Review
Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients
by Egidio Imbalzano, Luana Orlando, Giuseppe Dattilo, Marianna Gigliotti De Fazio, Giuseppe Camporese, Vincenzo Russo, Alessandro Perrella, Francesca Futura Bernardi and Pierpaolo Di Micco
Medicina 2024, 60(1), 156; https://doi.org/10.3390/medicina60010156 - 15 Jan 2024
Viewed by 873
Abstract
Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and treatment of venous thromboembolism and for the treatment of [...] Read more.
Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and treatment of venous thromboembolism and for the treatment of acute coronary syndrome. Furthermore, the use of enoxaparin has been extended to other clinical situations that require antithrombotic pharmacological prevention, such as hemodialysis and recurrent abortion. In this review, we report the main clinical experiences of using enoxaparin in the prevention of VTE in nonsurgical patients. Full article
(This article belongs to the Special Issue Emergency Medicine in Haemostasis Disorders)
Back to TopTop